Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:AEZSNASDAQ:ASNDNASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsAEZSAeterna Zentaris$3.34-0.9%$3.48$3.96▼$12.00$5.99M1.557,305 shs640 shsASNDAscendis Pharma A/S$172.60+0.2%$166.65$111.09▼$183.00$10.53B0.37497,597 shs420,195 shsRGCRegencell Bioscience$17.04-2.1%$0.00$0.08▼$83.60$8.60B2.451.59 million shs800,501 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+6.51%AEZSAeterna Zentaris0.00%+1.21%-2.08%+9.87%-24.43%ASNDAscendis Pharma A/S0.00%-2.65%+5.41%+10.50%+26.28%RGCRegencell Bioscience0.00%-54.22%+1,739,999,900.00%+1,739,999,900.00%+1,739,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti Pharma1.7194 of 5 stars3.50.00.00.00.00.81.3AEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AASNDAscendis Pharma A/S3.5119 of 5 stars4.53.00.00.02.31.70.6RGCRegencell Bioscience0.3737 of 5 stars0.03.00.00.02.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideAEZSAeterna Zentaris 0.00N/AN/AN/AASNDAscendis Pharma A/S 3.00Buy$220.6727.85% UpsideRGCRegencell Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ASND, RGC, AEZS, and ACST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.004/16/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AAEZSAeterna Zentaris$2.37M2.52N/AN/A$14.99 per share0.22ASNDAscendis Pharma A/S$393.54M26.81N/AN/A($1.88) per share-91.81RGCRegencell BioscienceN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A719.17N/A-93.22%N/A-33.29%9/2/2025 (Estimated)RGCRegencell Bioscience-$4.30MN/A0.00∞N/AN/AN/AN/AN/ALatest ASND, RGC, AEZS, and ACST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AAEZSAeterna ZentarisN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86AEZSAeterna ZentarisN/A5.945.93ASNDAscendis Pharma A/SN/A1.040.71RGCRegencell BioscienceN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%AEZSAeterna Zentaris0.73%ASNDAscendis Pharma A/SN/ARGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%AEZSAeterna Zentaris0.10%ASNDAscendis Pharma A/S40.00%RGCRegencell BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/AASND, RGC, AEZS, and ACST HeadlinesRecent News About These CompaniesRegencell Bioscience Appoints New Independent Director Amid Board ChangesJune 30 at 2:51 PM | tipranks.comRegencell Bioscience Reports Improved Financial Results for First Half of 2025June 30 at 2:51 PM | tipranks.comMystery $42 billion Chinese medical fortune collapses in daysJune 27 at 5:09 PM | msn.comRegencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can ExplainJune 27 at 5:09 PM | finance.yahoo.comRegencell Bioscience Holdings Limited (RGC) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRGC - Regencell Bioscience Holdings Ltd Price vs Fair Value | MorningstarJune 26, 2025 | morningstar.comMRegencell Bioscience (NASDAQ:RGC) Trading Down 3.5% - Here's WhyJune 26, 2025 | marketbeat.comRegencell Bioscience Holdings Ltd (RGC)June 22, 2025 | investing.comRegencell Bioscience Holdings (NasdaqCM:RGC) Announces 38:1 Stock Split Effective June 2025June 20, 2025 | finance.yahoo.comThe company recently effected a 38-for-1 forward stock splitJune 20, 2025 | msn.comWhy This Chinese Herbal Medicine Stock Backed by BlackRock and Morgan Stanley Gained 50,000% in 6 Months Despite Posting LossesJune 20, 2025 | msn.comA Chinese herbal-medicine stock with no revenue has surged 60,000% this year. 5 things to know about the company's mysterious spike.June 20, 2025 | msn.comPrediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to ImplodeJune 20, 2025 | fool.comRegencell Bioscience: Fundamentals And Meme Stock Potential Are Both LackingJune 18, 2025 | seekingalpha.comRegencell Bioscience: The Most Overvalued Stock In BiotechJune 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASND, RGC, AEZS, and ACST Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Aeterna Zentaris NASDAQ:AEZS$3.34 -0.03 (-0.89%) As of 06/27/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Ascendis Pharma A/S NASDAQ:ASND$172.60 +0.38 (+0.22%) As of 04:00 PM EasternAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Regencell Bioscience NASDAQ:RGC$17.04 -0.36 (-2.07%) As of 04:00 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
